Sharing impressions, exchanging insights, and discussing the future... On November 23, in the Party and Mass Activities Room of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, 20 Party members sat together, each taking turns to express their thoughts and experiences in studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee. The atmosphere was vibrant and enthusiastic, with everyone brimming with confidence about the future.

In the Party and Mass Activities Room of Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shisiyao Group, Party members are studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee.

Meanwhile, the plaza in front of the raw-material receiving area at Hebei Guangxiang Pharmaceutical is bustling with activity: forklifts shuttle back and forth as 54 tons of caffeine API are being loaded onto trucks. Boxed trucks are meticulously prepared and poised to depart for the port, with this shipment scheduled to arrive at ports in Germany and Thailand more than a month from now.
“Over the past few days, we have earnestly studied the spirit of the Sixth Plenary Session of the 19th CPC Central Committee, which emphasized high-quality development and the comprehensive deepening of reform and opening-up, thereby charting the course and bolstering our confidence for corporate growth. Our company is focusing on core technologies and continuously intensifying R&D and innovation, with new technologies and products now serving as a new driving force for high-quality enterprise development,” said Cui Yongbin, Chairman of Hebei Guangxiang Pharmaceutical Co., Ltd. “The decision to establish our operations in the Bohai New Area of Cangzhou was also driven by our recognition of the boundless business opportunities arising from the coordinated development of the Beijing–Tianjin–Hebei region.”
Hebei Guangxiang Pharmaceutical was completed and put into operation in the Bohai New Area of Cangzhou in 2019. It serves as a supporting project for Shijiazhuang Sihua Pharmaceutical Group to leverage the historic opportunities presented by the coordinated development of the Beijing–Tianjin–Hebei region, promote industrial transformation, strengthen and extend the industrial chain, and accelerate the implementation of its “APIs plus formulations” strategic layout.
Cui Yongbin stated that Hebei Guangxiang Pharmaceutical primarily manufactures active pharmaceutical ingredients such as caffeine, metronidazole, and theophylline. The company has developed more than 40 high-value-added and innovative APIs, including refined, serialized, and high-end formulations, and holds 12 core patents; 95% of its products are exported. Since the beginning of this year, Hebei Guangxiang Pharmaceutical has been vigorously promoting a dual-circulation strategy in both domestic and international markets. During the first three quarters, both production and sales remained robust, with sales revenue increasing by 209% quarter-on-quarter. In particular, export value surged by more than 300% in the third quarter. The company anticipates an annual output value of 70 million tons and annual sales exceeding US$200 million, with major exports to European and American countries such as the United States, Germany, Canada, and Austria.
Stepping into Workshop 603—The Theophylline Synthesis Unit—at Hebei Guangxiang Pharmaceutical, one sees no production staff; instead, three or four operators are seated at computers in the control room. The process flows sequentially through crude-theophylline primary purification, filtration, crude-theophylline secondary purification, and another round of filtration. A flowchart of the theophylline production process is posted on the wall, while the clean production environment, clear status indicators, and brightly lit, well-maintained equipment convey a strong sense of standardized, meticulous management.
“Our current production process is highly intelligent and automated. In the global API market, price is only one factor; quality and low carbon emissions are even more critical,” Cui Yongbin explained.
Unremitting efforts in innovation, quality, environmental protection, and cost control are the secret to Hebei Guangxiang Pharmaceutical’s success in global markets.
The eight large characters “Green Pharmaceutical Production, Harmonious Coexistence” on the office building of Hebei Guangxiang Pharmaceutical are strikingly prominent.
Construction is currently being expedited at the site of Phase II of the biochemical wastewater treatment system for the Hebei Guangxiang Pharmaceutical Plant.
“As active pharmaceutical ingredients (APIs) go global, clean and low-carbon production is the right path. Green pharmaceutical manufacturing is our corporate development philosophy,” said Cui Yongbin. “We are currently constructing Phase II of our wastewater treatment biochemical system, which is expected to be commissioned in February 2022. This project incorporates internationally advanced MBBR biofluidized-bed technology, which can rapidly enhance the treatment capacity and efficiency of the reaction tanks while improving the system’s shock resistance. Upon completion, the wastewater treatment capacity will double. The application of these green, low-carbon technologies and equipment will further fully unlock environmental and cost advantages.”
Hebei Guangxiang Pharmaceutical has also, for the first time in the pharmaceutical industry, implemented advanced technologies such as high-temperature wet oxidation for COD reduction, MVR desalination, catalytic ozone oxidation, and biochemical treatment, resulting in COD discharge levels that are significantly lower than national standards.
Dr. Zhu Shujie, a chemist with a Ph.D., serves as the Deputy General Manager of Hebei Guangxiang Pharmaceutical. “After studying the spirit of the Sixth Plenary Session of the 19th CPC Central Committee, I have been deeply moved. The session emphasized advancing self-reliance and strength in science and technology, and as a Party member and a young scientific and technological professional, I feel an enormous sense of responsibility,” said Dr. Zhu Shujie.
“Technical quality is the core of corporate development,” said Zhu Shujie. “Focusing on API production, we have continuously tackled key challenges and optimized our processes. By leveraging microreaction technology and continuous crystallization technology, we have resolved numerous technical hurdles—such as caking—that have long plagued API manufacturing. As a result, product quality has improved markedly, enabling us to meet the demands of overseas markets.”
“Our products leverage China’s leading crystal-form control technology, enabling precise manipulation of particle size and bulk density to meet the diverse requirements of high-end customers in Europe and North America. At the same time, this technology significantly enhances key quality attributes such as flowability for compounds like caffeine and metronidazole, giving our products a clear edge in market comparisons,” said Zhu Shujie with pride. Since commencing production in 2019, Hebei Guangxiang Pharmaceutical has successively obtained national GMP certification as well as international certifications including BRC, FSSC 22000, KOSHER, and HALAL.
“Going forward, we will continuously intensify our R&D efforts to develop more specialty APIs, thereby contributing to the high-quality development of enterprises and to the nation’s drive for scientific and technological self-reliance and strength,” said Zhu Shujie.
Touching moments are shared through communication, and warmth flows throughout the “Learning Hall.” “We have made the spirit of the plenary session a central focus of our Party branch’s ‘Three Meetings and One Lesson’ activities, employing a combination of collective study, individual self-study, and both online and offline formats to ensure comprehensive, top-down learning. As a result, everyone is highly motivated and is earnestly translating the spirit of the plenary session into concrete actions that drive high-quality development,” said Yang Huiling, Secretary of the Party Branch of Hebei Guangxiang Pharmaceutical.
“The company places great emphasis on leveraging the exemplary and leading role of Party members. We make full use of the Guangxiang Pharmaceutical WeChat group to organize Party study sessions for all Party members and to provide real-time updates on learning materials. Moving forward, we will translate the spirit of the plenary session into a powerful driving force for excelling in our respective duties, unite all employees as one, stay committed to our posts, demonstrate dedication and professionalism, and make due contributions to advancing industrial upgrading and high-quality development during the 14th Five-Year Plan period.” Under the guidance of the spirit of the plenary session, Yang Huiling is fully confident in the company’s future development.

(Reprinted from Great Wall Net, JiYun)